Skip to content

Study · Animal study (in vivo) · mouse · 2006

10 results

Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency.

Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J

Endocrinology18 May 2006Cited by 48 (Europe PMC)

PMID16709615 (opens in a new tab)DOI10.1210/en.2005-1537 (opens in a new tab)PepBankPUB-16709615
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant suppressed endogenous IGF-I gene transcription.

    In plain wordsIn wild-type mice, pegvisomant reduced natural IGF-I gene activity.

    Peptide
    Pegvisomant
    Outcome
    DecreaseEndogenous IGF-I transcription in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In WT mice, the GH antagonist pegvisomant (Peg) suppressed the transcription of endogenous IGF-I and acid-labile subunit (ALS) genes with no effect on IGF-binding protein 3 (IGFBP-3) mRNA.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant suppressed acid-labile subunit gene transcription.

    In plain wordsIn wild-type mice, pegvisomant reduced acid-labile subunit gene activity.

    Peptide
    Pegvisomant
    Outcome
    DecreaseALS transcription in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In WT mice, the GH antagonist pegvisomant (Peg) suppressed the transcription of endogenous IGF-I and acid-labile subunit (ALS) genes with no effect on IGF-binding protein 3 (IGFBP-3) mRNA.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant had no effect on IGFBP-3 mRNA.

    In plain wordsIn wild-type mice, pegvisomant did not change IGFBP-3 gene activity.

    Peptide
    Pegvisomant
    Outcome
    No significant changeIGFBP-3 mRNA in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In WT mice, the GH antagonist pegvisomant (Peg) suppressed the transcription of endogenous IGF-I and acid-labile subunit (ALS) genes with no effect on IGF-binding protein 3 (IGFBP-3) mRNA.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant-induced GH deficiency severely reduced circulating ALS.

    In plain wordsIn wild-type mice, pegvisomant strongly reduced circulating acid-labile subunit.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCirculating ALS in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consequently, Peg-induced GH deficiency in WT mice severely reduced ALS, IGF-I, and IGFBP-3 in the circulation and caused a severe growth deficit.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant-induced GH deficiency severely reduced circulating IGF-I.

    In plain wordsIn wild-type mice, pegvisomant strongly reduced blood IGF-I.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCirculating IGF-I in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consequently, Peg-induced GH deficiency in WT mice severely reduced ALS, IGF-I, and IGFBP-3 in the circulation and caused a severe growth deficit.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant-induced GH deficiency severely reduced circulating IGFBP-3.

    In plain wordsIn wild-type mice, pegvisomant strongly reduced blood IGFBP-3.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCirculating IGFBP-3 in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consequently, Peg-induced GH deficiency in WT mice severely reduced ALS, IGF-I, and IGFBP-3 in the circulation and caused a severe growth deficit.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In wild-type mice, pegvisomant-induced GH deficiency caused a severe growth deficit.

    In plain wordsIn wild-type mice, pegvisomant severely reduced growth.

    Peptide
    Pegvisomant
    Outcome
    DecreaseGrowth in WT mice
    Study

    mousen: not reported in source

    Wild-type mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Consequently, Peg-induced GH deficiency in WT mice severely reduced ALS, IGF-I, and IGFBP-3 in the circulation and caused a severe growth deficit.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In TTR-IGF-I mice, pegvisomant reduced endogenous IGF-I gene mRNA.

    In plain wordsIn TTR-IGF-I mice, pegvisomant reduced natural IGF-I gene activity.

    Peptide
    Pegvisomant
    Outcome
    DecreaseEndogenous IGF-I mRNA in transgenic mice
    Study

    mousen: not reported in source

    TTR-IGF-I transgenic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In TTR-IGF-I mice, Peg reduced the mRNA of the endogenous IGF-I gene with no effect on the TTR-IGF-I transgene expression, leading to a blunted decrease in serum IGF-I levels.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In TTR-IGF-I mice, pegvisomant did not affect TTR-IGF-I transgene expression.

    In plain wordsIn TTR-IGF-I mice, pegvisomant did not change activity of the added IGF-I gene.

    Peptide
    Pegvisomant
    Outcome
    No significant changeTTR-IGF-I transgene expression
    Study

    mousen: not reported in source

    TTR-IGF-I transgenic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In TTR-IGF-I mice, Peg reduced the mRNA of the endogenous IGF-I gene with no effect on the TTR-IGF-I transgene expression, leading to a blunted decrease in serum IGF-I levels.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In TTR-IGF-I mice, pegvisomant produced a blunted decrease in serum IGF-I.

    In plain wordsIn TTR-IGF-I mice, pegvisomant produced a limited decrease in blood IGF-I.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF-I in transgenic mice
    Study

    mousen: not reported in source

    TTR-IGF-I transgenic mice
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In TTR-IGF-I mice, Peg reduced the mRNA of the endogenous IGF-I gene with no effect on the TTR-IGF-I transgene expression, leading to a blunted decrease in serum IGF-I levels.
    1 context sentence
    Summary · context
    To define the contribution of circulating IGF-I to the endocrine regulation of somatic growth and the GH/IGF-I axis, we constructed a transgene with the transthyretin (TTR) enhancer/promoter and the mouse IGF-I cDNA and generated TTR-IGF-I transgenic mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.